Objectives: Knowledge of contemporary epidemiology of candidaemia is essential. We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia.
Introduction
Candida bloodstream infections are increasing, with Candida spp. the most common healthcare-associated bloodstream pathogen in some US centres. 1 -3 Resistance of the causative Candida to the initial antifungal agent chosen may result in delay in appropriate treatment and contributes to high mortality (≈40%). 4 In the USA and northern Europe, candidaemia caused by Candida glabrata, which is less susceptible to antifungal drugs, has increased. 3,5 -7 However, C. glabrata is less prevalent in Latin America and Asia with, for example, Candida tropicalis as the most common pathogen in India. 8, 9 Periodic surveillance is essential because of species-specific antifungal susceptibilities and changes in susceptibility over time. The emergence of echinocandin-resistant, and azole and echinocandin co-resistant strains of C. glabrata is of particular concern.
5, 10 -13 Candidaemia surveillance in Australia from 2002 to 2004 revealed an incidence of 1.8/10
5 population/year, with Candida albicans responsible for 47.3% and C. glabrata, 16.2% of cases 14 ; data on echinocandin susceptibility were not collected as these drugs were not licensed in Australia at commencement of the study. Given the importance of contemporary local epidemiology in selecting antifungal therapy, we conducted a follow-up study of candidaemia to identify changes in incidence, species epidemiology and antifungal susceptibility patterns.
Methods
Human research ethics committees (HRECs) at participating sites approved the study (HREC reference: AU RED LNR14/WMEAD/112).
Episodes of candidaemia were identified by active prospective laboratory-based blood culture surveillance as in a previous survey 14 in 29 microbiology laboratories. Each site contributed consecutive cases over a period of 12 months from August 2014 to July 2015, but commenced enrolment +5 months from August 2014 due to time variation in HREC approvals. Five additional laboratories declined participation, but provided the numbers of episodes over the 12 months; these data were included in the numerator for population-based incidence.
An episode was defined as the incident isolation of Candida from blood within the 1 year period. Polycandidal blood cultures concurrently contained at least two Candida species. Standardized data were collected: blood culture system, patient age and sex, Candida species, method of identification and antifungal susceptibility.
Microbiological methods
All laboratories cultured blood in BACTEC FX or 9240 (Becton Dickinson, Sparks, MD, USA) or BacT/Alert 3D (bioMérieux, Marcy-l'Étoile, France) systems. Candida isolates were identified using MALDI-TOF MS for 485 of 548 (89%) isolates; other methods included Vitek 2YST (n ¼ 34 isolates), 20C AUX or ID 32C systems (bioMérieux) (n¼14).
Reference laboratories (Westmead Hospital or SA Pathology) confirmed species identity by MALDI-TOF MS (Biotyper database v3.1; Bruker Daltoniks, Germany), and internal transcribed spacer rDNA sequencing, and performed susceptibility testing. Internal transcribed spacer sequencing 15 was performed on isolates that had MS scores of ,2.00 and for uncommon Candida spp. Susceptibility testing was performed using the Sensititre w YeastOne w YO10 system (Trek Diagnostics, Cleveland, OH, USA) and MIC values were interpreted according to CLSI clinical breakpoints; where there were no clinical breakpoints, species-specific epidemiological cut-off values were used to define isolates as WT or non-WT. 16 ,17
Statistics
Population incidence was calculated using denominator data from the 2014 Australian census. 18 Hospital-specific incidences were calculated using the denominator of different-day patient separations (defined as completed admissions) for the study period. Multiple pairwise comparisons of MICs between species employed the Kruskal -Wallis H-test with Dunn-Bonferroni post-hoc analysis. Data were analysed with SPSS version 21 (IBM Corp., Armonk, NY, USA).
Results
Of 549 candidaemia episodes, 527 (526 patients) yielding 548 Candida isolates were evaluable. One patient was candidaemic twice, 59 days apart. Confirmed species identity and antifungal susceptibility data were available for 498 of 548 (91%) isolates.
The population-based incidence of candidaemia was 2.41/10 
Candida species
Candida isolates included C. albicans (221 of 498, 44.4%), C. glabrata complex (n¼ 133, 26.7%) and Candida parapsilosis complex (n¼ 82, 16.5%). Uncommon Candida spp. were Candida lusitaniae (n¼ 10), Candida dubliniensis (n¼ 8), Candida lipolytica (n¼ 4) and 1 each of Candida guilliermondii, Candida kefyr and Candida quercitrusa ( Figure 1 ). Amongst C. glabrata complex, 128 were C. glabrata sensu stricto, 4 Candida bracarensis and 1 Candida nivariensis. Most (68 of 82; 82.9%) C. parapsilosis isolates were C. parapsilosis sensu stricto (Figure 1 ). Polycandidal candidaemia Chapman et al. (Table 1) .
Overall, C. albicans was susceptible to/exhibited WT MICs of all four azoles (Table 1) . Two (0.9%) isolates were resistant to fluconazole, cross-resistant to voriconazole and had non-WT MICs of itraconazole (.16 mg/L) and posaconazole (.8 mg/L). Ninetyeight per cent (81 of 82) of the C. parapsilosis complex were susceptible to both fluconazole and voriconazole; the single resistant strain was non-WT to posaconazole, but WT to itraconazole. Candida metapsilosis and Candida orthopsilosis isolates were susceptible/WT to the azoles and all 13 Candida krusei isolates were susceptible/WT to voriconazole, itraconazole and posaconazole.
The fluconazole MIC 90 for 24 C. tropicalis (4.8%) isolates was 64 mg/L. Six (25%) tested non-susceptible with four of six classed as resistant (Table 1) , also resistant to voriconazole and with non-WT MICs of posaconazole (.0.25 mg/L).
17 A further 13 were non-WT to posaconazole, totalling 17 (71%) non-WT isolates to posaconazole.
The geometric mean MIC of fluconazole for 132 C. glabrata complex isolates was 8.39 mg/L (Table 1); 9 (6.8%) were resistant to fluconazole (MIC ≥64 mg/L) and all had non-WT MICs of voriconazole (MIC ≥1 mg/L); 4 were also non-WT to posaconazole and itraconazole. All C. bracarensis and C. nivariensis isolates were susceptible-dose dependent/WT to all azoles. Uncommon Candida species had low MICs of azoles (Table 1) except for two C. lipolytica isolates, one C. lusitaniae isolate and one C. quercitrusa isolate with fluconazole MICs of 4, 32 and 4 mg/L, respectively. Echinocandin MICs were low for all Candida spp. (Table 1) . Only one C. glabrata isolate had a caspofungin MIC of 0.5 mg/L and was classified as resistant 16 ; however, its micafungin and anidulafungin MICs were ,0.008 and 0.03 mg/L, respectively. Another C. glabrata isolate and one C. parapsilosis isolate had micafungin MICs of 0.15 and 4 mg/L, respectively (intermediate susceptibility), but were caspofungin and anidulafungin susceptible.
Multiple pairwise comparisons between species showed the mean rank MICs of the azoles for C. albicans were significantly (a ¼ 0.05) less than those for the C. glabrata complex and C. 
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tropicalis isolates. There was no significant difference in mean rank MICs for C. tropicalis versus C. glabrata for all azoles. Mean rank echinocandin MICs for C. glabrata were significantly higher than those for C. albicans.
Discussion
Echinocandins have become first-line agents for the treatment of invasive candidiasis 19, 20 and the emergence of MDR C. glabrata is concerning. This study provides an important update on Candida trends in Australia.
Despite a modest rise in the annual population-based candidaemia incidence (2.41/10 5 cf. 1.8/10 5 ), 14 the incidence remains lower than that in the USA (8 -14/10 5 ), 6, 7, 19 Denmark and Spain (7 -10.1/10 5 ). 2, 3 Comparison of hospital-based incidences is problematic due to inter-study differences in choice of denominators and in study populations. In an Indian ICU-specific survey the incidence was 6.51/1000 admissions.
9 Jurisdiction-specific differences in incidence in our study re-emphasize the variability between regions across a country or locales. 8 A nearly 1.7-fold proportional increase (to 26.7%) in C. glabrata candidaemia signalled an increase from 2004, 14 now comparable to the USA in the mid-2000s and in some European centres. 3, 6, 21 The reason for this lag is uncertain. C. glabrata infection is associated with prior azole use, stem cell transplantation and older age (.65 years). 21 Whilst our study was not designed to identify risks for C. glabrata, the median patient age rose from 56 years in 2004 to 63 years.
14 C. bracarensis and C. nivariensis were uncommon (3.8% of C. glabrata complex).
Comparison of rare Candida infections (5% herein) between studies is confounded by methodological differences in speciation. We encountered only one case of C. guilliermondii candidaemia, which is more prevalent in South America. 8 The single patient with C. quercitrusa infection highlights this emerging pathogen, which can cause nosocomial infection. 22 Overall, resistance to the azoles and echinocandins was uncommon. Notably only 6.8% of C. glabrata isolates were fluconazole and voriconazole resistant. These isolates also had non-WT MICs of posaconazole, suggesting the presence of resistance mechanisms, which could affect therapeutic responses. In comparison, azole-resistant C. glabrata in the USA ranges between 9.7% and 30%. 10, 11, 21 Whilst methodological problems with caspofungin susceptibility testing 12 are well-known, the single caspofungin-resistant isolate and lack of anidulafungin or micafungin resistance, contrasts with echinocandin-resistance rates of 3%-23% in the USA, Denmark and India, where prior echinocandin exposure was the most significant risk for resistance. 9 -13 Further, we found no combined azole/echinocandin resistance (versus 11.1% -14.8% in the USA). 11, 13 This is reassuring as echinocandins are preferred therapy for C. glabrata infections. 19, 20 Whether echinocandin resistance will emerge in Australia with longer duration of use of these agents is uncertain. That 16.7% of C. tropicalis isolates were fluconazole-and voriconazoleresistant and that 71% of isolates were non-WT to posaconazole is also noteworthy, contrasting with results (,2% resistance) from an earlier study of ours (SC-A. Chen, T. Sorrell, M. Slavin, D. Ellis and D. Marriott, unpublished results). In Asia azole-resistance rates of 2%-8.1% are reported. 9, 23 In conclusion, the epidemiology of candidaemia in Australia has seen a substantial increase in C. glabrata. Overall, azole and echinocandin resistance remains uncommon though azole resistance may be emerging in C. tropicalis.
